Brief: Bbp-418 Demonstrates Potential To Be Disease Modifying Therapy, Restoring Cardiac And Disease Markers To Unaffected Levels
05/10/2026 12:40
BRIEF-Bbp-418 Demonstrates Potential To Be Disease Modifying Therapy, Restoring Cardiac And Disease Markers To Unaffected Levels Oct 5 (Reuters) - BridgeBio Pharma, Inc. BBIO.O:
BBP-418 DEMONSTRATES POTENTIAL TO BE DISEASE MODIFYING THERAPY, RESTORING CARDIAC AND DISEASE MARKERS TO UNAFFECTED LEVELS
BRIDGEBIO PHARMA - 100% OF BBP-418-TREATED LGMD2I/R9 PATIENTS NORMALIZE HS TROPONIN I AT MONTH 12
BRIDGEBIO PHARMA - BBP-418 UNDER FDA PRIORITY REVIEW WITH PDUFA DATE NOVEMBER 27, 2026
BRIDGEBIO PHARMA - BBP-418 MET ALL PRIMARY AND SECONDARY ENDPOINTS AT 12-MONTH INTERIM PHASE 3 FORTIFY TRIAL
Source text: ID:nGNX87kX3V
Further company coverage: BBIO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BridgeBio Pharma
See all newsU.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
U.S. STOCKS ON THE MOVE-Constellation Energy, AMD
BridgeBio rises on FDA priority review for dwarfism drug
Brief: Bridgebio Announces FDA Acceptance And Priority Review Of NDA For Oral Infigratinib For Children With Achondroplasia
Brief: Bbp-418 Demonstrates Potential To Be Disease Modifying Therapy, Restoring Cardiac And Disease Markers To Unaffected Levels